REDX PHARMA PLC
("Redx" or the "Company")

Result of Annual General Meeting

Alderley Park, UK, 14 March 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that its Annual General Meeting was held at 11am on 14 March 2024, with all resolutions passed by substantial majorities.

The table below sets out the details of the votes put to shareholders:

<table>
<thead>
<tr>
<th>Resolution number</th>
<th>Resolution name</th>
<th>Number of votes for &amp; discretionary</th>
<th>% of votes for &amp; discretionary</th>
<th>Number of votes against</th>
<th>% of votes against</th>
<th>% of votes withheld*</th>
<th>Total votes cast (including withheld)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Receive the Company’s annual accounts</td>
<td>351,887,218</td>
<td>94.48%</td>
<td>20,551,504</td>
<td>5.52%</td>
<td>0.00%</td>
<td>372,438,722</td>
</tr>
<tr>
<td>2</td>
<td>Re-appoint Ernst &amp; Young as auditors</td>
<td>372,434,833</td>
<td>100.00%</td>
<td>2,586</td>
<td>0.00%</td>
<td>0.00%</td>
<td>372,438,722</td>
</tr>
<tr>
<td>3</td>
<td>Elect Dr Joseph Anderson as a director</td>
<td>372,408,267</td>
<td>99.99%</td>
<td>3,889</td>
<td>0.00%</td>
<td>0.01%</td>
<td>372,438,722</td>
</tr>
<tr>
<td>4</td>
<td>Re-elect Dr Jane Griffiths as a director</td>
<td>372,407,145</td>
<td>99.99%</td>
<td>5,011</td>
<td>0.00%</td>
<td>0.01%</td>
<td>372,438,722</td>
</tr>
<tr>
<td>5</td>
<td>Re-elect Peter Presland as a director</td>
<td>351,851,226</td>
<td>94.47%</td>
<td>20,558,505</td>
<td>5.52%</td>
<td>0.01%</td>
<td>372,438,722</td>
</tr>
<tr>
<td>6</td>
<td>Re-elect Dr Robert Scott as a director</td>
<td>351,854,954</td>
<td>94.47%</td>
<td>20,557,202</td>
<td>5.52%</td>
<td>0.01%</td>
<td>372,438,722</td>
</tr>
<tr>
<td>7</td>
<td>Authorise the directors to allot shares</td>
<td>372,396,854</td>
<td>99.99%</td>
<td>41,868</td>
<td>0.01%</td>
<td>0.00%</td>
<td>372,438,722</td>
</tr>
<tr>
<td>8</td>
<td>Disapply pre-emption rights</td>
<td>372,266,621</td>
<td>99.96%</td>
<td>164,843</td>
<td>0.04%</td>
<td>0.00%</td>
<td>372,438,722</td>
</tr>
</tbody>
</table>

*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes ‘For’ or ‘Against’

For further information, please contact:

Redx Pharma Plc
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com

T: +44 (0)1625 469 918

SPARK Advisory Partners (Nominated Adviser)
Matt Davis/ Adam Dawes

T: +44 (0)203 368 3550

WG Partners LLP (Joint Broker)
Claes Spång/ Satheesh Nadarajah/ David Wilson

T: +44 (0)203 705 9330
Panmure Gordon (UK) Limited (Joint Broker)  
Rupert Dearden/ Freddy Crossley/ Emma Earl  
T: +44 (0)207 886 2500

FTI Consulting  
Simon Conway/ Ciara Martin  
T: +44 (0)203 727 1000

About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and is undergoing a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development with healthy volunteer data expected by the end of 2024. Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data during the first half of 2024, following which Redx will seek a partner for ongoing development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGGPUAUWUPCGGC